5th Nasal Formulation & Delivery Summit 2027

 

Navigate Drug-Device Compatibility, Predictive Clinical Translation, CMC, Regulatory Pathways for Combination Products, & Investment Strategy to Advance Best in Class Intranasal Delivery

Intranasal delivery is at a tipping point. The first approved nose-to-brain therapy has validated the approach, while easier administration, delivery efficiency, and lifecycle management opportunities are driving investment across multiple therapeutic areas.

With a growing wave of innovative biotechs reporting promising clinical results and the industry anticipating its next landmark approval, intranasal drug delivery has never offered greater opportunity or excitement.

The 5th Nasal Formulation & Delivery Summit is uniting leading biotechs, pharma, and investors to optimize drug and device compatibility, overcome challenges in formulation, and navigate commercial strategy and investment to optimize efficient drug delivery.

From optimizing nose-to-brain delivery and improving bioavailability to navigating funding opportunities, join 70+ CEOs, CSOs, and Heads of R&D, Formulation, and CMC to advance intranasal treatment for CNS, emergency-use, neurological, and infectious diseases for patient efficacy.

More Info

---

---